Search Result

Results for "

TrkA Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Trk Receptor (108) 5-HT Receptor (8) Adrenergic Receptor (5) Akt (6) Anaplastic lymphoma kinase (ALK) (10) Apoptosis (28) Autophagy (12) Bcl-2 Family (1) Bcr-Abl (1) c-Fms (3) c-Kit (4) c-Met/HGFR (7) Casein Kinase (1) Caspase (1) CDK (5) Checkpoint Kinase (Chk) (1) Discoidin Domain Receptor (2) Dopamine Receptor (3) Dopamine Transporter (4) Drug Metabolite (1) E1/E2/E3 Enzyme (2) EGFR (3) ERK (7) FAK (1) FLT3 (8) GSK-3 (1) Histamine Receptor (5) IFNAR (1) IGF-1R (2) iGluR (2) Insulin Receptor (2) Interleukin Related (1) Isotope-Labeled Compounds (3) Itk (2) JAK (1) JNK (3) Ligands for Target Protein for PROTAC (1) mAChR (5) MAP3K (1) Neurokinin Receptor (1) p62 (2) PAK (1) PDGFR (1) Pim (1) PKC (3) Polo-like Kinase (PLK) (2) Potassium Channel (4) PROTACs (3) Reference Standards (11) RET (3) ROS Kinase (8) Serotonin Transporter (5) Sodium Channel (5) STAT (1) STK33 (1) TAM Receptor (2) Tie (1) Tyrosinase (1) VEGFR (5)
By Research Areas:	Cancer (92) Cardiovascular Disease (1) Endocrinology (6) Infection (1) Inflammation/Immunology (15) Metabolic Disease (1) Neurological Disease (30)

By Targets:

Trk Receptor (108)

5-HT Receptor (8)

Adrenergic Receptor (5)

Akt (6)

Anaplastic lymphoma kinase (ALK) (10)

Apoptosis (28)

Autophagy (12)

Bcl-2 Family (1)

Bcr-Abl (1)

c-Fms (3)

c-Kit (4)

c-Met/HGFR (7)

Casein Kinase (1)

Caspase (1)

CDK (5)

Checkpoint Kinase (Chk) (1)

Discoidin Domain Receptor (2)

Dopamine Receptor (3)

Dopamine Transporter (4)

Drug Metabolite (1)

E1/E2/E3 Enzyme (2)

EGFR (3)

ERK (7)

FAK (1)

FLT3 (8)

GSK-3 (1)

Histamine Receptor (5)

IFNAR (1)

IGF-1R (2)

iGluR (2)

Insulin Receptor (2)

Interleukin Related (1)

Isotope-Labeled Compounds (3)

Itk (2)

JAK (1)

JNK (3)

Ligands for Target Protein for PROTAC (1)

mAChR (5)

MAP3K (1)

Neurokinin Receptor (1)

p62 (2)

PAK (1)

PDGFR (1)

Pim (1)

PKC (3)

Polo-like Kinase (PLK) (2)

Potassium Channel (4)

PROTACs (3)

Reference Standards (11)

RET (3)

ROS Kinase (8)

Serotonin Transporter (5)

Sodium Channel (5)

STAT (1)

STK33 (1)

TAM Receptor (2)

Tie (1)

Tyrosinase (1)

VEGFR (5)

By Research Areas:

Cancer (92)

Cardiovascular Disease (1)

Endocrinology (6)

Infection (1)

Inflammation/Immunology (15)

Metabolic Disease (1)

Neurological Disease (30)

125

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Trk Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12678

Entrectinib Maximum Cited Publications 28 Publications Verification NMS-E628; RXDX-101	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy	Cancer
Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of *TrkA/B/C, ROS1* and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .

HY-12866

Larotrectinib 15+ Cited Publications LOXO-101; ARRY-470	Trk Receptor Apoptosis	Cancer
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-103022

Repotrectinib 5+ Cited Publications TPX-0005	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK)	Cancer
Repotrectinib (TPX-0005) is a potent ROS1 (IC₅₀=0.07 nM) and TRK (IC₅₀=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC₅₀=1.01 nM). Repotrectinib has anti-cancer activity .

HY-14721

Tepotinib 5+ Cited Publications EMD-1214063	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects .

HY-13491

GNF-5837 4 Publications Verification	Trk Receptor	Cancer
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC₅₀ values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and *Tel-TrkA*, respectively) .

HY-50867

Lestaurtinib 4 Publications Verification CEP-701; KT-5555	JAK FLT3 Trk Receptor Apoptosis STAT	Cancer
Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the *TrkA/B/C* domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC₅₀s of 2, 25 and 0.9 nM for FLT3, *TrkA* and JAK2, respectively. Lestaurtinib induces apoptosis and cycle arrest, also can inhibit growth of tumor .

HY-108466

Ro 08-2750 4 Publications Verification	Apoptosis	Neurological Disease Cancer
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC₅₀ of ~ 1 μM. Ro 08-2750 inhibits NGF binding to p75 ^NTR selectively over TRKA . Ro 08-2750 is a selective _{MSI RNA-binding} activity inhibitor, with an IC₅₀ of 2.7 μM .

HY-10200

BMS-754807 10+ Cited Publications	IGF-1R Insulin Receptor	Endocrinology Cancer
BMS-754807 is a potent and reversible IGF-1R/IR inhibitor (IC₅₀=1.8 and 1.7 nM, respectively; K_i=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC₅₀ values of 6, 44, 7, 4, 9, and 25 nM, respectively .

HY-101977

Selitrectinib 5 Publications Verification LOXO-195	Trk Receptor	Cancer
Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for *TRKA* and TRKC, respectively .

HY-18314

GW 441756 5+ Cited Publications	Trk Receptor Apoptosis	Neurological Disease Cancer
GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (TrkA) inhibitor (IC₅₀=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth .

HY-P99297

Bedinvetmab ZTS-00508841	Trk Receptor	Inflammation/Immunology
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-148811

Zurletrectinib ICP-723	c-Met/HGFR Trk Receptor	Cancer
Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC₅₀ = 0.81 nM; TRKB IC₅₀ = 0.145 nM; TRKC IC₅₀ = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma .

HY-12866A

Larotrectinib sulfate 15+ Cited Publications LOXO-101 sulfate; ARRY-470 sulfate	Trk Receptor Apoptosis	Cancer
Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-137465

CG428	PROTACs Trk Receptor	Cancer
CG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 *TPM3-TRKA* fusion protein in KM12 colorectal carcinoma cells (DC₅₀ = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC₅₀ = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma .

HY-15590

AZ-23 3 Publications Verification AZD1332	Trk Receptor	Cancer
AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC₅₀s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

HY-122616

PF-06273340	Trk Receptor	Neurological Disease
PF-06273340 is a peripherally restricted pan-Trk inhibitor with IC₅₀ values of 6, 4, 3 nM for *TrkA, TrkB, and TrkC* receptors. PF-06273340 binds in a DFG-out conformation, targeting less conserved kinase ligand binding domain regions outside the ATP binding pocket. PF-06273340 exhibits anti-hyperalgesic and analgesic effects. PF-06273340 can be used for the research of pain .

HY-17603

Belizatinib 1 Publications Verification TSR-011	Anaplastic lymphoma kinase (ALK) Trk Receptor	Cancer
Belizatinib (TSR-011) is an orally active, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC₅₀ of 0.7 nM for wild-type recombinant ALK kinase.

HY-20878

Tyrphostin AG 879 3 Publications Verification AG 879	Trk Receptor EGFR Apoptosis	Cancer
Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits *TrKA* phosphorylation (IC₅₀ of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC₅₀ of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity .

HY-114331

DLK-IN-1	MAP3K FLT3 PAK STK33 Trk Receptor	Neurological Disease
DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a K_i value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and *TrkA. DLK-IN-1 reduces p-c-Jun*. DLK-IN-1 can be used in Alzheimer's disease research .

HY-129634

TrkA-IN-1	Trk Receptor	Neurological Disease
TrkA-IN-1 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor with an IC₅₀ of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activity .

HY-145587

Paltimatrectinib PBI-200; PPI-5278	Tyrosinase Trk Receptor	Inflammation/Immunology Cancer
Paltimatrectinib (compound I-147) is a potent tyrosine kinase inhibitor with an IC₅₀ of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases .

HY-112436

PF-6683324 Trk-IN-4	Trk Receptor	Neurological Disease
PF-6683324 (Trk-IN-4) is a potent pan-Trk inhibitor in cell-based assays with IC₅₀s of 1.9 nM, 2.6 nM and 1.1 nM for *TrkA, TrkB* and TrkC, respectively . Anti-hyperalgesic effect .

HY-114357A

DS-1205b free base	TAM Receptor c-Met/HGFR Trk Receptor	Cancer
DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC₅₀ of 1.3 nM. DS-1205b free base also inhibits MER, MET, and *TRKA, with IC₅₀s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit* cell migration in vitro and tumor growth in vivo .

HY-14721R

Tepotinib (Standard) EMD-1214063 (Standard)	Reference Standards c-Met/HGFR Autophagy	Cancer
Tepotinib (Standard) is the analytical standard of Tepotinib. This product is intended for research and analytical applications. Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation. Tepotinib has antitumor effects .

HY-149912

CZS-241	Polo-like Kinase (PLK) Trk Receptor Apoptosis	Cancer
CZS-241 is an orally active and selective inhibitor of Polo-like Kinase (PLK) 4 (IC₅₀=2.6 nM). CZS-241 inhibits *TRKA* with an IC₅₀ value of 2.74 μM. CZS-241 induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines .

HY-151948

TrkA-IN-3	Trk Receptor	Neurological Disease
TrkA-IN-3 is a potent, subselective and allosteric *TrkA* inhibitor, with an IC₅₀ of 22.4 nM. TrkA-IN-3 shows more than 8000-fold selectivity for TrkA over TrkB and TrkC. TrkA-IN-3 can be used for the research of pain .

HY-151949

TrkA-IN-4	Trk Receptor	Neurological Disease
TrkA-IN-4, a potent, orally active and allosteric *TrkA* inhibitor, is a proagent of TrkA-IN-3 (IC₅₀=22.4 nM, HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects .

HY-157542

CG428-NEG	Trk Receptor PROTACs	Others
CG428-NEG is a TRK degrader negative control. CG428 (HY-137465) inhibits cell growth and reduce TPM3-TRKA levels .

HY-112471

**TrkA Inhibitor**	CDK	Cancer
TrkA Inhibitor (Compound 18) is a CDK2 inhibitor with an IC₅₀ of 0.69  μM over CDK1. TrkA Inhibitor can be used for chemotherapy-induced alopecia research .

HY-122906

JTE-952	c-Fms	Inflammation/Immunology
JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC₅₀ values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis .

HY-112437

PF-06737007	Trk Receptor	Neurological Disease
PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with IC₅₀s of 7.7 nM, 15 nM and 3.9 nM for *TrkA, TrkB* and TrkC, respectively . Anti-hyperalgesic effect .

HY-14721A

Tepotinib hydrochloride EMD-1214063 hydrochloride	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects .

HY-135096

Amitriptyline-d3 hydrochloride	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease
Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride). Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a *TrkA* and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity .

HY-171450

VMD-928	Trk Receptor	Cancer
VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent *TrkA* ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-141864

ITK/TRKA-IN-1	Itk	Inflammation/Immunology
ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC₅₀ value of 1.0 nM and 96 % inhibition, respectively.

HY-P991622

MNAC13	Trk Receptor	Neurological Disease Inflammation/Immunology
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human *TrkA. MNAC13 inhibits* the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain .

HY-131244

ALK-IN-9	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-9 (compound 40) is a potent ALK inhibitor. ALK-IN-9 inhibits cell proliferation with IC₅₀s of <0.2 nM, <0.2 nM, 0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), KG-l cell (OP2-FGFR1), respectively .

HY-112423

CE-245677	Trk Receptor Tie	Cardiovascular Disease Cancer
CE-245677 is a potent reversible inhibitor of Tie2 and *TrkA/B* kinases with a cellular IC₅₀s of 4.7 and 1 nM.

HY-175271

JWJ-01-378	PROTACs Trk Receptor ERK	Cancer
JWJ-01-378 is a selective TRK PROTAC degrader. JWJ-01-378 efficiently degrades WT TRK and TPM3-TRKA fusion proteins and inhibits downstream pERK signaling, while showing limited efficacy against TRK inhibitor resistant mutants and ALK fusions. JWJ-01-378 potently suppresses cancer cell proliferation .Pink: TRK ligand (HY-160520); Blue: CRBN ligase ligand (HY-103596); Black: linker

HY-146697

IHMT-TRK-284	Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis	Cancer
IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC₅₀ values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent *TrkA* ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-124637

ALE-0540	Trk Receptor	Neurological Disease
ALE-0540, a nonpeptidic small molecule, is a nerve growth factor receptor antagonist. ALE-0540 inhibits the binding of NGF to tyrosine kinase (Trk) A or both p75 and TrkA with IC₅₀ values of 5.88 μM and 3.72 μM, respectively. ALE-0540 can be used to examine mechanisms leading to the development of agents for the study of pain .

HY-157168

TrkA-IN-6	Trk Receptor	Neurological Disease
TrkA-IN-6 (compound R48) is a hydrazone-like, selective inhibitor of tropomyosin kinase type A receptor kinase (TrkA). TrkA-IN-6 exhibited a higher cytotoxic effect on U87 GBM cells than Temozolomide (HY-17364), with an IC₅₀ of 68.99 μM .

HY-178142

Multi-kinase-IN-7	EGFR VEGFR Trk Receptor CDK FAK Akt GSK-3 Apoptosis Caspase Bcl-2 Family	Cancer
Multi-kinase-IN-7 is a multikinase inhibitor with IC₅₀s of 2.19, 2.95, 3.59 and 9.31 μM against EGFR, VEGFR2, *TrKA* and CDK2, respectively. Multi-kinase-IN-7 shows moderate and weaker activity against FAK, AKT1, GSK3β and CDK5 with IC₅₀ values of 6.3, 9.2, 11.7 and 23.4 μM, respectively. Multi-kinase-IN-7 displays broad spectrum antiproliferative potential against NCI cancer cell lines. Multi-kinase-IN-7 induces cell cycle arrest, apoptosis and necrosis. Multi-kinase-IN-7 Inhibitor can be used for the study of breast cancer .

HY-172802

TrkA-IN-10	Trk Receptor	Cancer
TrkA-IN-10 (PI-15R) is a *TrkA* inhibitor with the IC₅₀ values of 17 nM, 8 nM, and 5 nM for *TrkA, TrkB* and TrkC, respectively. TrkA-IN-10 can be used in cancer research .

HY-169546

TrkA-IN-7	Trk Receptor	Cancer
TrkA-IN-7 (Compound 4) is an inhibitor of Tropomyosin Receptor Kinase A (TrkA) with a K_d value of 40 μM .

HY-161775

RET/TRKA-IN-1	RET Trk Receptor	Cancer
RET/TRKA-IN-1 (Compound 13) is a dual inhibitor for RET (IC₅₀=0.375 µM) and *TRKA. RET/TRKA-IN-1 inhibits* cell viability of LC-2 and KM12, with GI₅₀ of 0.72 and 0.25 μM. RET/TRKA-IN-1 arrests the cell cycle at G1 phase .

HY-161819

TRK-IN-29	Trk Receptor	Cancer
TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor (IC₅₀: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKA ^G595R, TRKA ^F589L, TRKA ^G667C, TRKA and TRKC respectively). TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties .

Cat. No.	Product Name	Target	Research Area

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent *TrkA* ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent *TrkA* ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between *TrkA* and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99297

Bedinvetmab ZTS-00508841	Trk Receptor	Inflammation/Immunology
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .

HY-P991622

MNAC13	Trk Receptor	Neurological Disease Inflammation/Immunology
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human *TrkA. MNAC13 inhibits* the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain .

HY-P991323

MEDI-1912	Trk Receptor Neurokinin Receptor	Inflammation/Immunology
MEDI-1912 is a human monoclonal antibody (mAb) targeting NGF/bNGF. MEDI-1912 inhibits signaling through *TrkA* and p75 receptors. MEDI-1912 can be used in chronic pain research .

HY-P992345

DS002	Trk Receptor	Neurological Disease
DS002 is a human monoclonal antibody targeting NGF/bNGF, with an IC₅₀ of 6.60 nM against human NGF, 1.98 nM against rat NGF, and 8.46 nM against mouse NGF. DS002 blocks *NGF-TrkA* binding, interrupts pain signal transduction, inhibits *TrkA*-mediated downstream signaling pathways, and alters aromatic amino acid metabolic pathways. DS002 inhibits cancer cell proliferation. DS002 exerts a preventive effect on Paclitaxel-, Cisplatin- and Vincristine-induced peripheral neuropathy in rats. DS002 can be used in studies related to chronic pain and chemotherapy-induced peripheral neuropathy .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10546

Ganglioside GM1	Structural Classification Natural Products Animals	iGluR Trk Receptor ERK Apoptosis Autophagy
Ganglioside GM1 is a type of glycosphingolipid, mainly found on the cell membranes of the central nervous system of vertebrates. Ganglioside GM1 exerts neuroprotective effects by reducing excessive activation of NMDAR, activating *TrkA* and ERK1/2, and inhibiting oxidative stress and cell apoptosis and autophagy. Ganglioside GM1 can be used in the research of diseases such as traumatic brain injury, Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Cat. No.	Product Name	Chemical Structure

HY-12678S1

Entrectinib-d8

Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC₅₀ values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice .

HY-B0527AS

Amitriptyline-d6 hydrochloride

Amitriptyline-d₆ hydrochloride is the deuterium labeled Amitriptyline hydrochloride (HY-B0527A). Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (K_i = 3.45 nM) and NET (K_i = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with K_i = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (K_i = 11-24 nM), H1 receptors (K_i = 0.5-1.1 nM), adrenergic α1 receptors (K_i = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC₅₀ = 4.78 μM) and it has cardiotoxicity.

HY-12678S

Entrectinib-d4

Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks